Drug Trial Radar · NCT03964233
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Jun 20, 2019
Primary completion
Sep 5, 2024
Study completion Feb 6, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has 2 parts. The first part of the study is done. The first part was open to adults with different types of advanced cancer (solid tumors). The second part is open to people with specific types of soft tissue sarcoma, advanced lung cancer, and cancer in the stomach, bladder or bile ducts. The participants get a combination of 2 medicines called brigimadlin (also called BI 907828) and ezabenlimab (also called BI 754091). Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor). When the study started, some participants got a third medicine called BI 754111 in addition. Treatment with BI 754111 was stopped because data from another study showed no additional effect of BI 754111. The purpose of the first part of the study was to find out the highest dose of brigimadlin that the participants could tolerate in combination with ezabenlimab. This dose is used in the second part of the study. The purpose of the second part is to see whether the combination of brigimadlin with ezabenlimab is able to make tumors shrink. The participants are in the study as long as they benefit from treatment and can tolerate it. Ezabenlimab treatment is limited to 2 years. During this time, they get infusions of ezabenlimab, and take tablets with brigimadlin every 3 weeks. The doctors check how many participants have health problems during the study. The doctors also monitor the size of the tumor.
Conditions
- Neoplasms
Interventions
BI 907828Drug
Film-coated tablets
ezabenlimabDrug
Solution for infusion
BI 754111Drug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia - maximum tolerated dose (MTD) of brigimadlin (BI 907828) in combination with ezabenlimab based on the number of patients with dose limiting toxicities (DLTs) during the first treatment cycleTime frame: Up to 21 Days
- Phase Ib - Objective response (OR)Time frame: Up to 24 months
- Phase Ib - Progression free survivalTime frame: Up to 24 months
Locations
23 sites in 11 countries. Site status is shown where the registry gives one.
Sarcoma Oncology Center
Santa Monica, California
Yale Cancer Center
New Haven, Connecticut
University Cancer and Blood Center
Athens, Georgia
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Oncology-Irving-69444
Irving, Texas
NEXT Oncology-San Antonio-65273
San Antonio, Texas
NEXT Virginia
Fairfax, Virginia
Linear Clinical Research
Nedlands, Western Australia, Australia
UZ Leuven
Leuven, Belgium
INS Bergonie
Bordeaux, France
CTR Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Universitätsklinikum Frankfurt
Frankfurt, Germany
Universitätsklinikum Ulm
Ulm, Germany
Central Hospital of Northern Pest - Military Hospital
Budapest, Hungary
National Cancer Center Hospital
Tokyo, Chuo-ku, Japan
Universitair Medisch Centrum Groningen
Groningen, Netherlands
National Cancer Centre Singapore
Singapore, Singapore
Hospital Universitari Vall D Hebron
Barcelona, Spain
Hospital Clínico San Carlos
Madrid, Spain
The Royal Marsden Hospital, Chelsea
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.